Roivant Sciences Ltd. $ROIV Shares Newly Purchased by Sumitomo Mitsui DS Asset Management Company Ltd

Key Points

• Sumitomo Mitsui DS Asset Management purchased 61,728 Roivant Sciences shares worth approximately $2.26 million in the third quarter, while institutional investors collectively own 64.76% of the company.
• Roivant insiders sold 1.82 million shares valued at roughly $65.85 million over the past 90 days, including CEO Eric Venker’s 200,000-share sale under a pre-arranged Rule 10b5-1 plan.
• Brepocitinib met both Phase 3 primary endpoints in non-infectious uveitis trials, potentially expanding Roivant’s commercial opportunity. Analysts maintain a “Moderate Buy” consensus with an average price target of $45.64.

Sumitomo Mitsui DS Asset Management Company Ltd bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 61,728 shares of the company's stock, valued at approximately $2,257,000.

Several other hedge funds have also added to or reduced their stakes in the stock. Cordatus Wealth Management LLC bought a new stake in Roivant Sciences during the 3rd quarter valued at $357,000. SteelPeak Wealth LLC purchased a new stake in shares of Roivant Sciences during the third quarter worth $309,000. Alpine Bank Wealth Management bought a new position in shares of Roivant Sciences in the third quarter worth $25,000. Vontobel Holding Ltd. bought a new position in shares of Roivant Sciences in the third quarter worth $363,000. Finally, State of Alaska Department of Revenue boosted its holdings in shares of Roivant Sciences by 13.3% in the third quarter. State of Alaska Department of Revenue now owns 60,716 shares of the company's stock worth $2,219,000 after acquiring an additional 7,142 shares during the period. Institutional investors own 64.76% of the company's stock.

Insider Transactions at Roivant Sciences

In related news, insider Mayukh Sukhatme sold 284,707 shares of the company's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. Following the transaction, the insider directly owned 18,630,739 shares in the company, valued at approximately $675,364,288.75. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $36.62, for a total transaction of $7,324,000.00. Following the completion of the sale, the chief executive officer directly owned 1,599,154 shares in the company, valued at $58,561,019.48. This represents a 11.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 1,822,688 shares of company stock valued at $65,848,636. 8.80% of the stock is owned by corporate insiders.

More Roivant Sciences News

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Brepocitinib met both Phase 3 primary endpoints. Roivant and Priovant reported that the CLARITY-1 and CLARITY-2 trials achieved their primary goals in non-infectious uveitis. The drug also delivered statistically significant and clinically meaningful improvements in key secondary measures, including sustained steroid-free disease control, reduced vascular leakage, resolution of macular edema and better patient-reported visual functioning. Roivant and Priovant announce positive brepocitinib Phase 3 results
• Positive Sentiment: The trial data could expand the drug’s commercial opportunity. Coverage highlighted brepocitinib’s ability to reduce reliance on steroids in inflammatory eye disease, while Roivant is expected to pursue a label expansion for Lisraya in uveitis. Positive commentary and analyst coverage contributed to the stock’s upward move. Roivant’s TYK2/JAK inhibitor reduces need for steroids
• Neutral Sentiment: Roivant will report fiscal second-quarter results on November 9, 2026. Investors will receive updated financial results and a business outlook, including any regulatory or commercialization plans related to brepocitinib. Roivant quarterly earnings announcement
• Negative Sentiment: CEO Eric Venker sold 200,000 shares worth approximately $7.0 million. The sale reduced his direct ownership by 12.5%, which may draw investor attention. However, it was executed under a pre-arranged Rule 10b5-1 trading plan, reducing its significance as a discretionary bearish signal. SEC insider transaction filing

Analysts Set New Price Targets

A number of analysts recently issued reports on ROIV shares. Citigroup reiterated a "buy" rating on shares of Roivant Sciences in a research note on Monday, October 12th. Cantor Fitzgerald restated an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, September 24th. UBS Group set a $55.00 target price on Roivant Sciences in a research note on Wednesday, September 9th. Wolfe Research lowered Roivant Sciences from an "outperform" rating to a "peer perform" rating in a report on Monday, October 12th. Finally, Stifel Nicolaus initiated coverage on Roivant Sciences in a research report on Wednesday, September 16th. They set a "buy" rating and a $51.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $45.64.

Roivant Sciences Price Performance

NASDAQ:ROIV opened at $37.45 on Friday. Roivant Sciences Ltd. has a 52-week low of $17.89 and a 52-week high of $42.50. The stock has a fifty day moving average of $36.61 and a 200 day moving average of $33.32.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. The business had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. Equities analysts predict that Roivant Sciences Ltd. will post -2.00 earnings per share for the current fiscal year.

Roivant Sciences Profile

Roivant Sciences Ltd. NASDAQ: ROIV is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant's research and development activities have included immunology, dermatology, women's health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.